Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05675865

Cryoablation for Monomorphic Ventricular Tachycardia

Led by Adagio Medical · Updated on 2026-04-07

206

Participants Needed

15

Research Sites

185 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio VT Cryoablation System in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT)

CONDITIONS

Official Title

Cryoablation for Monomorphic Ventricular Tachycardia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female 18 years or older
  • Clinical indication for catheter ablation due to ischemic and/or non-ischemic heart disease with recurrent symptomatic sustained scar-mediated monomorphic ventricular tachycardia
  • Diagnosis of ischemic cardiomyopathy with prior myocardial infarction and left ventricular ejection fraction between 20% and less than 50%
  • Diagnosis of non-ischemic cardiomyopathy with scar in territory without coronary stenosis confirmed by imaging within 90 days or intra-procedurally, with left ventricular ejection fraction between 20% and less than 50%
  • Diagnosis of arrhythmogenic right ventricular cardiomyopathy
  • Received a market-released Implantable Cardioverter Defibrillator before enrollment
  • At least one documented spontaneous episode of sustained monomorphic ventricular tachycardia within the previous 6 months
  • Refractory or intolerant to at least one Class III antiarrhythmic drug
  • Willingness and ability to participate in baseline and follow-up evaluations for the full length of the study
  • Willingness and ability to give informed consent
Not Eligible

You will not qualify if you...

  • Presence of intracardiac thrombus within 48 hours prior to procedure
  • Presence of isolated epicardial scar requiring epicardial ablation identified by imaging or intra-procedurally
  • Ventricular tachycardias due to idiopathic causes, automaticity, bundle branch reentry, focal tachycardia, or secondary to electrolyte imbalance or reversible non-cardiac causes
  • For non-ischemic cardiomyopathy patients: congenital conditions limiting ventricular access, severe valve diseases, active inflammatory processes within 120 days, sarcoidosis, hypertrophic cardiomyopathy, or drug/alcohol-induced cardiomyopathy
  • Any ventricular tachycardia ablation within 4 weeks prior to enrollment
  • More than one prior ventricular tachycardia ablation or surgical treatment within 2 years
  • Cardiogenic shock unless due to incessant monomorphic ventricular tachycardia
  • Severe cardiovascular conditions including Class IV heart failure, recent cardiac surgery or coronary intervention, cardiac devices or defects, recent acute myocardial infarction or unstable angina, mechanical heart valves, cardiac tumors, or significant congenital heart disease
  • Acute illness or active systemic infection
  • History of cryoglobulinemia
  • History of blood clotting or bleeding disorders
  • Peripheral vascular disease preventing left ventricular access
  • Contraindication to heparin
  • Allergy to radiographic contrast dye that cannot be managed prior to procedure
  • History of stroke, transient ischemic attack, or systemic embolism within 6 months prior to procedure
  • Pregnant or anticipating pregnancy during study follow-up
  • Current enrollment in another study that may interfere with this study's procedures or outcomes
  • Any condition making the patient a poor candidate for the procedure or study, including mental illness, addiction, end-stage illness with less than 12 months life expectancy, ventricular assist device, or candidacy for heart transplantation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

Banner University Medical Center Phoenix

Phoenix, Arizona, United States, 85006

Actively Recruiting

2

University of California San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

3

Johns Hopkins University

Baltimore, Maryland, United States, 21287

Actively Recruiting

4

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

5

University of Michigan

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

6

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Actively Recruiting

7

Weill Cornell Medical Center

New York, New York, United States, 10065

Actively Recruiting

8

Northwell Health- Staten Island University Hospital

Staten Island, New York, United States, 10305

Actively Recruiting

9

Ohio State University

Columbus, Ohio, United States, 43210

Actively Recruiting

10

Hospital of University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

11

Medical Center of South Carolina (MUSC)

Charleston, South Carolina, United States, 29403

Actively Recruiting

12

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

13

Texas Cardiac Arrhythmia Research Institute (TCARF)

Austin, Texas, United States, 78705

Actively Recruiting

14

Montreal Heart Institute

Montreal, Quebec, Canada, H1T 1C8

Actively Recruiting

15

McGill University

Montreal, Quebec, Canada, H4A 3J1

Actively Recruiting

Loading map...

Research Team

N

Nabil Jubran

CONTACT

D

Doug Kurschinski

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here